- Home
- ESTA vs AUPH Comparison
ESTA vs AUPH Comparison
Compare ESTA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTA
- AUPH
- Stock Information
- Founded
- ESTA 2004
- AUPH 1993
- Country
- ESTA Costa Rica
- AUPH Canada
- Employees
- ESTA N/A
- AUPH N/A
- Industry
- ESTA Industrial Specialties
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ESTA Health Care
- AUPH Health Care
- Exchange
- ESTA Nasdaq
- AUPH Nasdaq
- Market Cap
- ESTA 982.3M
- AUPH 1.1B
- IPO Year
- ESTA 2018
- AUPH 1999
- Fundamental
- Price
- ESTA $37.81
- AUPH $7.77
- Analyst Decision
- ESTA Buy
- AUPH Strong Buy
- Analyst Count
- ESTA 6
- AUPH 2
- Target Price
- ESTA $55.50
- AUPH $11.50
- AVG Volume (30 Days)
- ESTA 361.2K
- AUPH 1.1M
- Earning Date
- ESTA 08-05-2025
- AUPH 07-31-2025
- Dividend Yield
- ESTA N/A
- AUPH N/A
- EPS Growth
- ESTA N/A
- AUPH N/A
- EPS
- ESTA N/A
- AUPH 0.27
- Revenue
- ESTA $170,235,000.00
- AUPH $247,295,000.00
- Revenue This Year
- ESTA $27.10
- AUPH $12.15
- Revenue Next Year
- ESTA $24.55
- AUPH $18.31
- P/E Ratio
- ESTA N/A
- AUPH $29.21
- Revenue Growth
- ESTA 9.27
- AUPH 29.20
- 52 Week Low
- ESTA $26.56
- AUPH $5.20
- 52 Week High
- ESTA $52.41
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- ESTA 55.04
- AUPH 38.94
- Support Level
- ESTA $36.36
- AUPH $8.08
- Resistance Level
- ESTA $38.96
- AUPH $8.29
- Average True Range (ATR)
- ESTA 1.80
- AUPH 0.19
- MACD
- ESTA -0.06
- AUPH -0.03
- Stochastic Oscillator
- ESTA 65.76
- AUPH 5.00
About ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.